NASDAQ: INVAInnoviva Inc Stock
$21.25+0.29 (+1.38%)
Updated Aug 18, 2026
INVA Price
$21.25
Fair Value Price
N/A
Market Cap
$1.54B
52 Week Low
$16.52
52 Week High
$25.15
P/E
4.21x
P/B
1.24x
P/S
3.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$440.00M
Earnings
$357.24M
Gross Margin
72.2%
Operating Margin
99.46%
Profit Margin
81.2%
Debt to Equity
0.38
Operating Cash Flow
$191M
Beta
0.37
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INVA Overview
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INVA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INVA
Ranked#101 of 464
Ranked#101 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.24 | A | |
| $118.10 | A | |
| $6.75 | A |
Be the first to know about important INVA news, forecast changes, insider trades & much more!
INVA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INVA is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INVA is good value based on its earnings relative to its share price (4.21x), compared to the US market average (15.03x)
P/E vs Market Valuation
INVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more INVA due diligence checks available for Premium users.
Valuation
INVA fair value
Fair Value of INVA stock based on Discounted Cash Flow (DCF)
Price
$21.25
Fair Value
$67.05
Undervalued by
68.31%
INVA is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
4.21x
Industry
18.39x
Market
15.03x
INVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INVA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
INVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.24x
Industry
5.4x
INVA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INVA's financial health
Profit margin
Revenue
$119.6M
Net Income
-$83.4M
Profit Margin
-69.8%
INVA's Earnings (EBIT) of $437.63M... subscribe to Premium to read more.
Interest Coverage Financials
INVA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7B
Liabilities
$469.5M
Debt to equity
0.38
INVA's short-term assets ($753.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INVA's short-term assets ($753.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INVA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$52.0M
Investing
-$55.3M
Financing
-$29.4M
INVA's operating cash flow ($191.49M)... subscribe to Premium to read more.
Debt Coverage Financials
INVA vs Biotech Stocks
Innoviva Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.